abstract
Future of Health Summit 2024

Drafting the Blueprint for the Next Era of Patient Engagement

-

During the last two decades, the R&D ecosystem has been transformed by a shift to more patient-centric approaches to biomedical R&D. But as the scope and scale of patient engagement expand, efforts to align regulatory requirements and guidance must keep pace to streamline and maximize efforts at including patients in R&D endeavors. In a new era, when patient engagement is increasingly becoming standard practice, 1) What approaches should regulators, individual patients, patient organizations, and industry sponsors use to keep pace with trends in patient engagement in the medtech, digital health, and AI spaces? 2) How do R&D stakeholders measure the value and ROI in patient engagement? 3) How is patient engagement impacting reimbursement, coverage, and value? 4) How is patient-experience data being better leveraged as a research and decision-support resource? Experts on this panel will discuss the current state of these trends and what actions can be taken now (in light of these trends) to optimize patient engagement in the future.

    Moderator

    Image

    Marc Boutin

    Board Member, Patient Focused Medicines Development

    Speakers

    Image

    Robyn Bent

    Director, CDER Patient Focused Drug Development Program, US Food and Drug Administration
    Image

    Ebony Dashiell-Aje

    Executive Director, Head, Patient Centered Outcomes Science, BioMarin Pharmaceutical Inc.
    Image

    Andrea Ferris

    President and CEO, LUNGevity
    Image

    Juan Garcia Burgos

    Head of Public and Stakeholder Engagement, European Medicines Agency
    Image

    Beth Meagher

    Vice Chair, US Federal Health Sector Leader, Deloitte